Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the publication of an in-depth review article by Chief Scientific Officer, Scott Chappel, Ph.D., regarding the role of mitochondria in improving fertility outcomes. Mitochondria are the energy source of all cells, and inadequate mitochondrial activity has been implicated in poor embryo development and pregnancy failures. Studies have shown that increasing mitochondrial function improves egg quality and the success of in vitro fertilization (IVF). OvaScience is developing a proprietary product, AUGMENTSM, to improve egg quality by adding a woman’s own mitochondria to her egg during IVF.
Help employers find you! Check out all the jobs and post your resume.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the publication of an in-depth review article by Chief Scientific Officer, Scott Chappel, Ph.D., regarding the role of mitochondria in improving fertility outcomes. Mitochondria are the energy source of all cells, and inadequate mitochondrial activity has been implicated in poor embryo development and pregnancy failures. Studies have shown that increasing mitochondrial function improves egg quality and the success of in vitro fertilization (IVF). OvaScience is developing a proprietary product, AUGMENTSM, to improve egg quality by adding a woman’s own mitochondria to her egg during IVF.
Help employers find you! Check out all the jobs and post your resume.
